1. The SNX-482 peptide from Hysterocrates gigas spider acts as an immunomodulatory molecule activating macrophages.
- Author
-
Munhoz J, Thomé R, Rostami A, Ishikawa LLW, Verinaud L, and Rapôso C
- Subjects
- Animals, Antigens, CD immunology, Cell Line, Tumor, Cell Polarity, Cytokines metabolism, Enzyme-Linked Immunosorbent Assay, Gene Expression, Macrophage Activation immunology, Mice, Neoplasms genetics, Neoplasms immunology, Spider Venoms pharmacology, Adjuvants, Immunologic pharmacology, Macrophage Activation drug effects, Spider Venoms chemistry, Spiders chemistry
- Abstract
Peptides are molecules that have emerged as crucial candidates for the development of anticancer drugs. Spider venoms are a rich source of peptides (venom peptides - VPs) with biological effects. VPs have been tested as adjuvants in the activation of cells of the immune system with the aim of improving immunotherapies for the treatment of neoplasms. In the present study, the effects of SNX-482, a peptide from the African tarantula Hysterocrates gigas, on macrophages were described. The results showed that the peptide activated M0-macrophages, increasing costimulatory molecules (CD40, CD68, CD80, CD83, CD86) involved in antigen presentation, and also augmenting the checkpoint molecules PD-L1, CTLA-4 and FAS-L; these effects were not concentration-dependent. SNX-482 also increased the release of IL-23 and upregulated the expression of ccr4, ifn-g, gzmb and pdcd1, genes important for the anticancer response. The pretreatment of macrophages with the peptide did not interfere in the modulation of T cells, and macrophages previously polarized to M1 and M2 profile did not respond to SNX-482. These findings represent the expansion of knowledge about the use of VPs in drug discovery, pointing to a potential new candidate for anticancer immunotherapy. Considering that most immunotherapies target the adaptive system, the modulation of macrophages (an innate immune cell) by SNX-482 is especially relevant., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF